AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01065402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PPB-R-203-Based Meal
Description: PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
Study NCT01065402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TK9-Based Meal
Description: TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
Study NCT00551512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP501 and Cisplatin
Description: CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
Study NCT01428154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
Study NCT03456505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.
Study NCT03456505 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Listening
Description: A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
Study NCT02348112 — intervention group
Intervention type: DEVICE
Intervention: Altis Single Incision Sling
Description: Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
Study NCT04192877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vagus Nerve Neurodynamic test
Description: The VN-NDT has been developed starting from the VN morphology selecting the physiological movements that induce the greater mechanical tension on the nerve. The subjects will be assessed supine on an examination table with assessors standing at the cranial short side of the table. Upper cervical flexion and contralateral lateral flexion had been selected for loading the intracranial portion. The ipsilateral neck rotation had been selected for loading the cervical tract. Keeping the subject's head in the final movements combination gentle movements of the upper abdomen caudally and cranially had been selected for loading the thoracic tract and used as discrimination maneuver. The test will be declared positive (indicating abnormal responses) if symptoms will be felt in anatomical regions other than the neck on the same side of the test and discrimination maneuvers changed the subject's symptoms indicating a neurogenic source, otherwise it will be declared negative.
Study NCT02979847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hybrid approach
Description: Before transseptal puncture, epicardial puncture is performed through subxyphoid approach. Atrial epicardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Endocardial potentials are also recorded in the same fashion. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
Study NCT02979847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional endocardial approach
Description: Atrial endocardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
Study NCT02803151 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
Study NCT02855437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVR (Phone call)
Description: IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
Study NCT02855437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RheumPro (Smartphone application)
Description: RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm.
Study NCT04878523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi berries juice
Description: Testing product
Study NCT00787215 — intervention group
Intervention type: OTHER
Intervention: observational: no treatment involved
Description: observational: no treatment involved
Study NCT01264770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib and placebo injections
Description: Fostamatinib 100mg twice daily and placebo injection once every two weeks
Study NCT01264770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib and placebo injections
Description: Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
Study NCT01264770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib and placebo injections
Description: Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
Study NCT01264770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab and placebo of fostamatinib
Description: Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
Study NCT01264770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of fostamatinib, fostamatinib, and placebo injections
Description: Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
Study NCT03570346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Subjects will be randomized into 3 dose groups orally twice daily.
Study NCT03570346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into 3 dose groups orally twice daily.
Study NCT02976103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jacki Recovery jacket
Description: An outer jacket that holds surgical drains and allows access for blood draws
Study NCT02976103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care Pain medicine/management
Description: Standard care pain medicine and management in hospitals where the study enrolls
Study NCT02976103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care Pain medicine/management
Description: Standard care pain medicine and management in hospitals where the study enrolls
Study NCT01985360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Catheterization
Description: Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
Study NCT04878523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Blank
Study NCT04267133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Facial video of detection of cardiac disease
Description: This project proposes to evaluate a non-contact video recording technology to detect the presence of AF. The technology extracts a pulsatile signal by measuring the subtle variations in skin color of a patient's face (flushing) due to the variations of blood volume underneath the skin. The technology uses a standard web camera. This technique is videoplethysmography (VPG).
Study NCT02140099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Relationships Plus Program (HRPP)
Description: The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
Study NCT02140099 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Condition (Classroom Activities)
Study NCT02293655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OROS-Methylphenidate (MPH)
Description: OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
Study NCT02293655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OROS-Methylphenidate (MPH)
Description: OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
Study NCT03566368 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: a 12 lead surface electrocardiogram taken after connecting limb and chest electrodes
Study NCT03566368 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiogram
Description: Transthoracic echocardiogram performed to evaluate Cardiac function in parasternal - long and short axis, Apical - 4 chamber and 5 chamber views.
Study NCT03566368 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac enzyme - Troponin I Levels
Description: Blood sample - venous collected to measure blood troponin - I levels.
Study NCT02558257 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
Study NCT03679910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CEMIP , CA19-9 ,CEA
Description: CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
Study NCT03679910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A) CBC . B) RBG. C)KFT. D) LFT.
Description: A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
Study NCT00413192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: 1.4 mg/m\^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
Study NCT01769833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-interferon-Alfa-2A
Description: Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
Study NCT01769833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nucleosides
Study NCT03696810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Laboratory tests
Description: • Laboratory tests (HbA1C levels and lipids)
Study NCT03318315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.
Study NCT03318315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza H7N9 vaccine
Description: Monovalent 2017 H7N9 inactivated influenza vaccine
Study NCT03318315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
Study NCT03318315 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
Study NCT03318315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)
Study NCT02475577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripherals with HealthInterlink technology
Description: home remote monitoring
Study NCT01985360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Graft Surgery
Description: Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart.
Study NCT01985360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
Study NCT01985360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: Diet, physical activity, smoking cessation
Study NCT01985360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Study NCT01300455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suvorexant
Description: 40 mg tablets, orally once daily for 4 consecutive days in the evening
Study NCT00774592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caribbean Informed Parents and Children Together (CImPACT)
Description: CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
Study NCT00774592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bahamian Focus on Older Youth (BFOOY)
Description: 10 session HIV prevention program
Study NCT01300455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 40 mg tablets, orally once daily for 4 consecutive days in the evening
Study NCT01300455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo tablets, orally once daily for 4 consecutive days in the evening
Study NCT01300455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Placebo tablets, orally once daily for 4 consecutive days in the evening
Study NCT03826862 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT three-dimensional reconstruction
Description: All patients will receive CT three dimensional reconstruction before surgery
Study NCT03013439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: The trial is a dose escalating trial.
Study NCT00005831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00005831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00005831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00005831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00005831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00150839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirtazapine
Description: Patients receive mirtazapine 45mg and placebo.
Study NCT00150839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Patients receive mirtazapine 45mg and venlafaxine 300mg.
Study NCT01107587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' human rotavirus vaccine 444563
Description: Oral, two doses.
Study NCT01107587 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, two doses.
Study NCT03331146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A placebo (saline infusion) will be administered after induction of general anesthesia.
Study NCT03331146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: A placebo (saline infusion) will be administered after induction of general anesthesia.
Study NCT03331146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Nitrite
Description: Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
Study NCT03331146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite
Description: Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
Study NCT00805623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: 1 cc of sucrose 33.5% with or without pacifier
Study NCT00805623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: 1 cc of sucrose 33.5% with or without pacifier
Study NCT03036787 — intervention group
Intervention type: BEHAVIORAL
Intervention: family based intervention
Description: behavioural advises to family for normal motor development
Study NCT02968563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets administered orally
Study NCT02968563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally
Study NCT02968563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously
Study NCT02909452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor
Study NCT02909452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: A selective humanized monoclonal antibody (mAb)
Study NCT02062333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
Study NCT02062333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esmolol
Description: 500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
Study NCT03442621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant Fasted
Description: Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast
Study NCT03442621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant with a high fat breakfast
Description: Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast